Subject: ONCX Fulfills an OTCQB Listing Requirement with Industry Vet and CEO Added as Independent Board Member

SCV Client Spotlight
BY READING THIS EMAIL YOU CERTIFY YOU HAVE READ THE DISCLAIMER BELOW AND THE FULL DISCLAIMER PROVIDED THROUGH A LINK AT THE END OF THIS EMAIL. This is a paid advertisement., Inc. is not responsible or held liable for the information in the press releases issued by the companies in these emails. Please always do your own due diligence.
Facebook Twitter YouTube
ONCX Fulfills an OTCQB Listing Requirement with Industry Vet and CEO Added as Independent Board Member
Hot Stock to WatchHot Stock to Watch

Company: Oncolix, Inc. (Pink Sheets: ONCX)


Price: 0.0774

Change (%): + 0.0154 (24.84)

Volume: 19,000
ONCX Chart

Oncolix, Inc. Expands Board of Directors with New Appointment

OTC-QB requirements are fulfilled with two independent board members appointed

HOUSTON, Dec. 04, 2017 (GLOBE NEWSWIRE) - Oncolix, Inc. (OTC PINK: ONCX) (the “Company”), a biotechnology company focused on gynecological cancers, announced the appointment of John W. Holaday, Ph.D., to the Company’s Board of Directors as an independent board member. The appointment brings the total size of the Board to four members, two of whom are independent, which fulfills an OTC-QB listing requirement.

“As an accomplished CEO of several biopharmaceutical companies, Dr. Holaday has an extensive track record of successfully leading his companies from the ground stages of preclinical research and clinical trials all the way through to product launches,” said Michael T. Redman, president and chief executive officer of Oncolix. “His expertise greatly expands Oncolix’s capabilities in developing Prolanta™ for ovarian cancer through clinical trials as well as for future indications and additions to the pipeline. In addition, with this appointment, we have now fulfilled OTC-QB requirements and expect to uplist soon.”

Dr. Holaday has a track record of accomplishments as a senior executive at several growing biopharmaceutical companies. Most recently, until his retirement in 2014, Dr. Holaday was co-founder, chief executive officer, managing director and board member of QRxPharma, a specialty pharmaceutical company headquartered in Sydney, Australia, where he directed the development and NDA submission of a better-tolerated opioid. Prior to founding QRx in 2007, he was co-founder of the technology-focused Harvest Bank of Maryland and co-founder and chief executive officer of EntreMed, Inc., a pioneering anti-angiogenesis company focused on oncology. He co-founded MaxCyte, a flow electroporation company. Prior to that, he was co-founder and executive vice president of Research and Development at Medicis Pharmaceutical Corp., a dermatology company acquired by Valeant Pharmaceuticals in 2012 for 2.6B. He is currently a board member for several biopharmaceutical companies and non-profit organizations. He earned his B.S. and M.S. from the University of Alabama, and his Ph.D. in Pharmacology from the University of California, San Francisco School of Medicine. He holds over 90 patents and has published over 230 scientific articles, book chapters and four books. He served as Chair of the BioAlliance of the Tech Council of Maryland. In 2006, he was named to the Ernst & Young’s Entrepreneur of the Year Hall of Fame.

Continue Reading

Like Us on FacebookFollow Us on Twitter

SmallCapVoice (SCV) is an electronic publication. Information sources for our profiles include, but are not limited to, online research, member suggestions, magazines, newspapers, analyst suggestions, publicly available material information provided by the profiled company, press releases and similar sources. This communication is not an offer to sell or a recommendation that you buy or sell any security. SCV holds no securities licenses and is not qualified to provide investment advice. We are compensated for these advertisements by the profiled companies. You should not use this newsletter as the sole basis for any investment decision. While all investments involve risk, microcap stocks are among the most risky. Many microcap companies have no proven track record. You should only invest in microcap companies if you can afford to lose your entire investment. You should consult a qualified, licensed financial advisor or stock broker before making any decisions to invest in the securities of any company that is described in these profiles. These profiles are paid advertisements. Although we have a reasonable belief that the information in each profile is accurate, we cannot guarantee that this information, which originates from third parties, is accurate. We do not have the resources to confirm the accuracy of all information obtained from third parties. It is important for you to verify all information by your own independent research. You are receiving this message because you have agreed to receive emails from You may opt out of our distribution list at any time by clicking on the “unsubscribe” link below. Link to full disclosure about compensation paid to, Inc. by companies featured on our website or in our e-mail communications.

About Penny Stocks